Drug intelligence / Profile preview

RGI-1000

Development stage: Preclinical
Lead developer: REGiMMUNE
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

RGI-1000 is part of REGiMMUNE's RGI-1000 series, developed using the company's proprietary reVax platform technology, which induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It is designed for the treatment of allergies, leveraging liposomal formulations similar to related compounds in the series that activate invariant natural killer T cells and promote Treg expansion to modulate immune responses without broad immunosuppression.[1][5][9]

Targets

iNKT TCR (Invariant natural killer T-cell receptor)

Beyond the preview

Go deeper on RGI-1000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGI-1000.

Explore the full profile